Devkota Ashwini K, Edupuganti Ramakrishna, Yan Chunli, Shi Yue, Jose Jiney, Wang Qiantao, Kaoud Tamer S, Cho Eun Jeong, Ren Pengyu, Dalby Kevin N
Texas Screening Alliance for Cancer Therapeutics, The University of Texas at Austin, 105 E. 24th Street, Stop A5300, Austin, TX 78712 (USA).
Chembiochem. 2014 Nov 3;15(16):2435-42. doi: 10.1002/cbic.201402321. Epub 2014 Sep 15.
eEF-2K is a potential target for treating cancer. However, potent specific inhibitors for this enzyme are lacking. Previously, we identified 2,6-diamino-4-(2-fluorophenyl)-4H-thiopyran-3,5-dicarbonitrile (DFTD) as an inhibitor of eEF-2K. Here we describe its mechanism of action against eEF-2K, on the basis of kinetic, mutational, and docking studies, and use chemoinformatic approaches to identify a similar class of carbonitrile-containing compounds that exhibit the same mechanism of action. We show that DFTD behaves as a reversible covalent inhibitor of eEF-2K with a two-step mechanism of inhibition: a fast initial binding step, followed by a slower reversible inactivation step. Molecular docking suggests that a nitrile group of DFTD binds within 4.5 Å of the active site Cys146 to form a reversible thioimidate adduct. Because Cys146 is not conserved amongst other related kinases, targeting this residue holds promise for the development of selective covalent inhibitors of eEF-2K.
真核生物延伸因子2激酶(eEF-2K)是治疗癌症的一个潜在靶点。然而,目前缺乏针对该酶的强效特异性抑制剂。此前,我们鉴定出2,6-二氨基-4-(2-氟苯基)-4H-硫代吡喃-3,5-二腈(DFTD)是eEF-2K的一种抑制剂。在此,我们基于动力学、突变和对接研究描述了其对eEF-2K的作用机制,并使用化学信息学方法鉴定出一类具有相同作用机制的含腈化合物。我们表明,DFTD作为eEF-2K的可逆共价抑制剂,具有两步抑制机制:快速的初始结合步骤,随后是较慢的可逆失活步骤。分子对接表明,DFTD的一个腈基在活性位点半胱氨酸146的4.5埃范围内结合,形成可逆的硫代亚氨酸酯加合物。由于半胱氨酸146在其他相关激酶中不保守,靶向该残基有望开发出eEF-2K的选择性共价抑制剂。